[ 177 Lu]Lu-Gemini

N/A

Report date: 2025/10/23 11:36:46

Base Information

Drug Name[ 177 Lu]Lu-Gemini

Drug Alias NameN/A

ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionCell surface A33 antigen binders

TargetsCell surface A33 antigen

Therapy Area/IndicationsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMemorial Sloan Kettering Cancer Center Weill Cornell Medicine The Rockefeller University

China Registration ClassN/A

Develop Information

Active CompaniesWeill Cornell Medicine Memorial Sloan Kettering Cancer Center The Rockefeller University

Inactive CompaniesN/A

Active IndicationsColorectal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A